News
Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA™ for the Middle East and North Africa region
News
Hikma launches a generic version of Afinitor® Tablets, 2.5mg, 5mg, 7.5mg
Update
Hikma update regarding COVID-19
Our impact
Every day, our medicines are used by approximately 13 million people. The impact we have on people's lives is important, positive and far-reaching.
Case study
Our support and impact for the Healthy Kitchen Project
Case study
Our support and impact; improving patient’s access to ritonavir
Insight
Two ways to minimise the impact of COVID-19 on vulnerable communities
News
Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP
Find out more
Who we are. We make high quality medicines and make them accessible to the people that need them.
Corporate social responsibility
Hikma launches employee matching donation campaign to support local US food banks and pantries
Find out more
Our commitment to sustainability
Find out more
We develop, manufacture and market nearly 700 quality branded and non-branded generic medicines worldwide.